{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.4","upperLimit":"47.6","value":"22.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Grade 3 or higher AE of any type, regardless of attribution.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Tivantinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Incidence of Adverse Events, Graded Per NCI CTCAE Version 4","type":"SECONDARY","unitOfMeasure":"percentage of participants"}